A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.
Prostate Cancer
DRUG: LBH589 (i.v. panobinostat)
To determine the MTD of i.v. LBH589 in combination with docetaxel and prednisone in patients with HRPC, determine if MTD occurs after every 3 - 6 pts
To compare the PK profile of i.v. LBH589 with and without docetaxel, PK assessment will occur during the first 2 weeks of each pt treatment. Minor safety throughout the study treatment phase|To determine safety and tolerability of i.v. LBH589 in combination with docetaxel and prednisone in patients with HRPC, PK assessment will occur during the first 2 weeks of each pt treatment|To determine preliminary activity of i.v. LBH589 in combination with docetaxel and prednisone, PK assessment will occur during the first 2 weeks of each pt treatment
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.